Last reviewed · How we verify

NCT07336862: BS-GLP

The Efficacy and Safety of Bariatric Surgery Combined With GLP-1 Receptor Agonists for Patients With Severe Obesity: A Prospective, Multicenter Cohort Study

Recruiting now Phase 1/Phase 2 Last updated 20 April 2026
What this trial tests

Phase 1/Phase 2 trial testing BS-GLP group in Obesity in 200 participants. Currently enrolling.

Timeline
1 January 2024
Primary endpoint
1 December 2027
1 December 2027

Quick facts

Lead sponsorChina-Japan Friendship Hospital
PhasePhase 1/Phase 2
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment200
Start date1 January 2024
Primary completion1 December 2027
Estimated completion1 December 2027
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

China-Japan Friendship Hospital

Who can join

Adults 18 to 60, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Obesity

Currently open trials in the same condition.

Other China-Japan Friendship Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07336862.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing